ClinicalTrials.gg
CompletedNCT05136404Updated Mar 17, 2025Results posted

A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants

A Phase 1 interventional study of Selpercatinib in Healthy, sponsored by Loxo Oncology, Inc.. Completed at 1 site in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-17.

Sponsored by Loxo Oncology, Inc. (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it, when given as three different formulations in adult healthy participants. The information about any adverse effects experienced will be collected and the tolerability of selpercatinib will also be evaluated. The study may last up to 59 days including the 28 days of screening period.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Loxo Oncology, Inc. is the lead sponsor of 17 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

First submitted after Loxo Oncology, Inc. became part of Eli Lilly and Company.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and vital signs
  • (BMI) within the range 18.0 to 35.0 kilograms per meter squared (kg/m²)

Exclusion criteria

Exclusion Criteria:

  • Have a history of allergic reactions to medications or food products
  • Have a abnormality of blood pressure and/or pulse rate as determined by the investigator
  • Clinically significant abnormalities on as determined by the investigator or prolongation of the or QTcF >450 msec at screening
  • Have clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to the planned start of selpercatinib
  • Have a history or presence of cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the product; or of interfering with the interpretation of data. Appendectomy, splenectomy, and cholecystectomy are considered as acceptable
  • Use of H2 blockers, proton pump inhibitors, and other drugs that affect selpercatinib exposure within 7 days of screening
  • Are intending to use over-the-counter or prescription medication, including dietary supplements, within 14 days prior to dosing and until study discharge (apart from occasional acetaminophen (≤2 g/24 hours), hormonal , or hormone replacement therapy)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Selpercatinib Sequence A:

    Period 1: 20 milligram (mg) Selpercatinib capsule single oral dose administered orally on Day 1. Period 2: 20 mg per milliliter (mL) Selpercatinib Powder for Oral suspension (PFOS) single oral suspension dose on Day 8. Period 3: 20 mg/mL Selpercatinib Ready to Use (RTU) single oral suspension on Day 15.

    Drug: Selpercatinib

  • Experimental
    Selpercatinib Sequence B

    Period 1: 20 mg/mL Selpercatinib RTU single oral suspension on Day 1. Period 2: 20 mg Selpercatinib capsule single oral dose administered orally on Day 8. Period 3: 20 mg/mL PFOS single oral suspension dose on Day 15.

    Drug: Selpercatinib

  • Experimental
    Selpercatinib Sequence C

    Period 1: 20 mg/mL PFOS single oral suspension dose on Day 1. Period 2: 20 mg/mL Selpercatinib RTU single oral suspension on Day 8. Period 3: 20 mg Selpercatinib capsule single oral dose administered orally on Day 15.

    Drug: Selpercatinib

Interventions

  • Administered orally

    Also known as: LY3527723, LOXO-292

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib

    PK: Cmax of Selpercatinib

    Time frame: Days 1, 8, and 15: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours (h) postdose

  2. PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Selpercatinib

    PK AUC\[0-∞\] of Selpercatinib

    Time frame: Days 1, 8, and 15: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 h postdose

  3. PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Selpercatinib

    PK: AUC\[0-tlast\] of Selpercatinib

    Time frame: Days 1, 8, and 15: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 h postdose

  4. PK: Time to Maximum Observed Concentration (Tmax) of Selpercatinib

    PK: Tmax of Selpercatinib

    Time frame: Days 1, 8, and 15: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 h postdose

07

Results

Posted Mar 17, 2025

Participant flow

Period 1
Participant flow — Period 1
MilestoneSelpercatinib Sequence A:Selpercatinib Sequence BSelpercatinib Sequence C
Started141414
Received atleast one dose of study drug141414
Completed141313
Not completed011
Withdrew: Adverse event011
Period 2
Participant flow — Period 2
MilestoneSelpercatinib Sequence A:Selpercatinib Sequence BSelpercatinib Sequence C
Started141313
Completed141312
Not completed001
Withdrew: Inappropriate behavior001
Period 3
Participant flow — Period 3
MilestoneSelpercatinib Sequence A:Selpercatinib Sequence BSelpercatinib Sequence C
Started141312
Completed141311
Not completed001
Withdrew: Adverse event001

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib

PK: Cmax of Selpercatinib

Time frame:
Days 1, 8, and 15: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours (h) postdose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib
nanograms per milliliter (ng/mL)20 mg Selpercatinib Capsule (Reference)20 mg Selpercatinib RTU Suspension (Test)20 mg/mL PFOS (Test)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib176 ± 64.2174 ± 36.9180 ± 39.8
Statistical analysis
  • 20 mg Selpercatinib Capsule (Reference) vs 20 mg Selpercatinib RTU Suspension (Test) · Mixed Models Analysis · Ratio of geometric least squares mean: 1.00 · 90% CI 0.937 to 1.08
  • 20 mg Selpercatinib Capsule (Reference) vs 20 mg/mL PFOS (Test) · Mixed Models Analysis · Ratio of geometric least squares mean: 1.04 · 90% CI 0.968 to 1.11
PrimaryPK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Selpercatinib

PK AUC\[0-∞\] of Selpercatinib

Time frame:
Days 1, 8, and 15: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 h postdose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Selpercatinib
nanogram*hour per milliliter (ng*hr/mL)20 mg Selpercatinib Capsule (Reference)20 mg Selpercatinib RTU Suspension (Test)20 mg/mL PFOS (Test)
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Selpercatinib2540 ± 28.02410 ± 29.02490 ± 27.0
Statistical analysis
  • 20 mg Selpercatinib Capsule (Reference) vs 20 mg Selpercatinib RTU Suspension (Test) · Mixed Models Analysis · Ratio of geometric least squares mean: 0.989 · 90% CI 0.953 to 1.03
  • 20 mg Selpercatinib Capsule (Reference) vs 20 mg/mL PFOS (Test) · Mixed Models Analysis · Ratio of geometric least squares mean: 1.02 · 90% CI 0.982 to 1.06
PrimaryPK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Selpercatinib

PK: AUC\[0-tlast\] of Selpercatinib

Time frame:
Days 1, 8, and 15: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 h postdose
Reported as:
Geometric mean · ng*hr/mL
PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Selpercatinib
ng*hr/mL20 mg Selpercatinib Capsule (Reference)20 mg Selpercatinib RTU Suspension (Test)20 mg/mL PFOS (Test)
PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Selpercatinib2180 ± 36.92160 ± 31.62190 ± 30.8
Statistical analysis
  • 20 mg Selpercatinib Capsule (Reference) vs 20 mg Selpercatinib RTU Suspension (Test) · Mixed Models Analysis · Ratio of geometric least squares mean: 1.01 · 90% CI 0.972 to 1.06
  • 20 mg Selpercatinib Capsule (Reference) vs 20 mg/mL PFOS (Test) · Mixed Models Analysis · Ratio of geometric least squares mean: 1.03 · 90% CI 0.992 to 1.08
PrimaryPK: Time to Maximum Observed Concentration (Tmax) of Selpercatinib

PK: Tmax of Selpercatinib

Time frame:
Days 1, 8, and 15: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 h postdose
Reported as:
Median · h
PK: Time to Maximum Observed Concentration (Tmax) of Selpercatinib
h20 mg Selpercatinib Capsule (Reference)20 mg Selpercatinib RTU Suspension (Test)20 mg/mL PFOS (Test)
PK: Time to Maximum Observed Concentration (Tmax) of Selpercatinib1.50 (1.00 to 24.02)1.50 (1.00 to 3.00)1.50 (1.00 to 3.50)
Statistical analysis
  • 20 mg Selpercatinib Capsule (Reference) vs 20 mg Selpercatinib RTU Suspension (Test) · Sign test · p = 0.4728 · Median difference (final values): 0.00 · 90% CI -0.50 to 0.00
  • 20 mg Selpercatinib Capsule (Reference) vs 20 mg/mL PFOS (Test) · Sign test · p = 0.0142 · Median difference (final values): 0.00 · 90% CI -0.50 to 0.00

Adverse events

Collected over Baseline up to 59 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Selpercatinib Sequence A:0/39 (0%)0/39 (0%)0/39 (0%)
Selpercatinib Sequence B:0/41 (0%)0/41 (0%)0/41 (0%)
Selpercatinib Sequence C:0/41 (0%)0/41 (0%)0/41 (0%)

Baseline characteristics

All participants who received at least one dose of Selpercatinib.

Age, Continuous
Age, Continuous(years)20 mg Selpercatinib
Mean42.0 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)20 mg Selpercatinib
Female13
Male29
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)20 mg Selpercatinib
Hispanic or Latino20
Not Hispanic or Latino22
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)20 mg Selpercatinib
American Indian or Alaska Native1
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American11
White29
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)20 mg Selpercatinib
United States42
08

Study locations

1 site
  • LabCorp CRU, Inc.
    Daytona Beach, Florida 32117, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Mar 2022, 3 months.

Results were first posted in Mar 2025, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2021
First posted
Nov 29, 2021
StartActual
Dec 3, 2021
Primary completionActual
Mar 14, 2022
CompletionActual
Mar 14, 2022
Results first posted
Mar 17, 2025
Last update
Mar 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05136404
Responsible party
Sponsor
First posted
Nov 29, 2021
Start date
Dec 3, 2021
Primary completion
Mar 14, 2022
Completion
Mar 14, 2022
Results posted
Mar 17, 2025
Last update
Mar 17, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selpercatinib

Start the discussion